Adalimumab (HUMIRA): a review

J Drugs Dermatol. 2003 Aug;2(4):375-7.


Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal* / adverse effects
  • Antibodies, Monoclonal* / pharmacokinetics
  • Antibodies, Monoclonal* / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid / drug therapy*
  • Biological Availability
  • Humans
  • Injections, Subcutaneous
  • Psoriasis / drug therapy
  • Randomized Controlled Trials as Topic


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Adalimumab